Side-by-side · Research reference
CagrilintidevsIGF-1 LR3
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
APhase 3HUMAN-REVIEWED35/64 cited
BAnimal-StrongHUMAN-REVIEWED10/58 cited
IGF-1 LR3
IGF-1 Analogue · Research
3–10×Potency vs IGF-I
Low IGFBPBinding affinity
ResearchStatus
Research only · SQ typical in animal models
01Mechanism of Action
Parameter
Cagrilintide
IGF-1 LR3
Primary target
Amylin receptor (AMYR) and calcitonin receptor (CTR) heterodimeric complexesBailey 2026
IGF-1 receptor (IGF-1R)McTavish 2009
Pathway
AMYR/CTR agonism → Central satiety signaling → Reduced food intake, delayed gastric emptying, suppressed glucagonBailey 2026
IGF-1R → IRS-1 → PI3K/Akt → Cell proliferation, protein synthesis, anti-apoptosisMuhlbradt 2009
Downstream effect
Central satiety induction, prandial glucagon suppression, reduced caloric intake, weight loss, improved glycemic controlBailey 2026Yamauchi 2026
Enhanced cell proliferation, muscle anabolism, inhibition of apoptosis, increased telomerase activity
Feedback intact?
Yes — acts via physiological amylin pathways
No — exogenous IGF analogue bypasses GH-mediated regulation
Origin
Second-generation non-aggregating long-acting amylin analogue designed for once-weekly dosingBailey 2026
Synthetic 83-AA analogue: 13-AA N-terminal extension + Arg substitution at position 3
Antibody development
—
—
02Dosage Protocols
Parameter
Cagrilintide
IGF-1 LR3
Standard dose (combination)
Cagrilintide 2.4 mg + Semaglutide 2.4 mg (CagriSema)Yamauchi 2026
Phase 3 REDEFINE 5 trial dosing.
—
Monotherapy dosing
Dose-dependent, under investigation
Monotherapy trials reported in meta-analysis.
—
Evidence basis
Phase 3 RCT (REDEFINE 5), meta-analysis of 3 RCTs (n=3545)Yamauchi 2026Ahmed 2026
Animal / in vitro only
Research dose (animal models)
—
Variable by protocol and species
In vivo murine atherosclerosis studies used sustained delivery.
In vitro typical concentration
—
10–1000 ng/mLThomas 2007
Dose-dependent effects on follicle growth and estradiol production.
Half-maximal stimulation
—
0.6 nM LR3 vs 1.5 nM native IGF-1Price 2004
2.5-fold greater potency in lung fibroblast proliferation.
Human use
—
Not FDA-approved; no published human trials
03Metabolic / Fat Loss Evidence
Parameter
Cagrilintide
IGF-1 LR3
Weight loss vs semaglutide
7.47% greater percentage weight lossAhmed 2026
CagriSema combination vs semaglutide monotherapy (meta-analysis).
—
Absolute weight change
Significantly greater absolute weight reductionAhmed 2026
Mean difference favoring combination therapy.
—
Mechanism
Central satiety inductionBailey 2026
IGF-1R activation → lipolytic signaling; secondary to anabolic effects
Glycemic benefit
Reduced fasting glucose and HbA1cAhmed 2026
Synergistic effect with semaglutide in combination.
—
Body composition
Predominant fat loss with weight reduction
—
Mitochondrial function
In vitro effects on skeletal muscle mitochondria under metabolic stress conditionsOld 2026
C2C12 myotube study; clinical relevance under investigation.
—
Key publications
REDEFINE 5 (Yamauchi 2026) · Ahmed meta-analysis 2026 · Bailey review 2026Yamauchi 2026Ahmed 2026Bailey 2026
—
Direct lipolytic evidence
—
Minimal — primarily anabolic/anti-apoptotic in literature
Atherosclerotic plaque effects
—
Reduced stenosis and core size in ApoE-KO micevon 2011
Plaque stabilization via vSMC phenotype modulation, not direct fat loss.
Human data
—
None published
04Side Effects & Safety
Parameter
Cagrilintide
IGF-1 LR3
Gastrointestinal
Nausea, diarrhea (common with incretin-based therapies)Pardali 2026
Dietary management and nutritional monitoring recommended.
—
Injection site reactions
Local reactions possible with subcutaneous administration
—
Safety profile
Generally consistent with incretin-based therapies
Phase 3 and meta-analysis safety data.
—
Tolerability
Tolerability considerations similar to GLP-1RAs
—
Muscle preservation
Lean mass considerations during weight loss
In vitro mitochondrial effects observed; clinical impact under investigation.
—
Hypoglycemia risk
—
Theoretical — IGF-1 analogues can lower blood glucose
Excessive cell proliferation
—
Mitogenic signaling; theoretical tumor promotion risk
Telomerase activation
—
2–10-fold increase in prostate cancer cells (PC-3, DU-145, LAPC-4)Wetterau 2003
Critically involved in cancer cell immortalization.
Oocyte degeneration
—
Increased oocyte degeneration at high doses (≥1000 ng/mL) in bovine folliclesThomas 2007
Unregulated anabolism
—
Bypasses physiological GH/IGF-1 feedback; no pulsatility control
Unknown human safety profile
—
No published human trials; safety data absent
Absolute Contraindications
Cagrilintide
- ·Hypersensitivity to cagrilintide or formulation components
IGF-1 LR3
- ·Active malignancy or history of cancer
- ·Not approved for human use
Relative Contraindications
Cagrilintide
- ·Severe gastrointestinal disease
- ·History of pancreatitis (incretin-based therapy consideration)
IGF-1 LR3
- ·Diabetes or glucose intolerance
- ·Family history of cancer
05Administration Protocol
Parameter
Cagrilintide
IGF-1 LR3
1. Dosing frequency
Once-weekly subcutaneous injection. Long-acting formulation designed for weekly administration schedule.Bailey 2026
IGF-1 LR3 is not FDA-approved for human use. All administration data derives from animal or in vitro studies.
2. Combination form
Co-formulated with semaglutide as CagriSema for single weekly injection combining amylin and GLP-1 receptor agonism.Yamauchi 2026Bailey 2026
Subcutaneous or intraperitoneal injection in animal models. In vitro: added directly to culture medium at concentrations of 10–1000 ng/mL.Thomas 2007
3. Injection site
Subcutaneous — typically abdomen, thigh, or upper arm. Rotate injection sites weekly to minimize local reactions.
Lyophilised powder reconstituted in sterile water or buffered saline per manufacturer protocol. Store at 2–8 °C after reconstitution.
4. Storage
Refrigerate 2–8°C. Follow product-specific storage instructions for pre-filled pens or vials. Protect from light.
Enhanced stability vs native IGF-1 due to reduced IGFBP binding; exact half-life in vivo not fully characterized in humans.
5. Dietary considerations
Nutritional monitoring recommended during treatment. Dietary management strategies important for tolerability and outcomes.Pardali 2026
—
06Stack Synergy
Cagrilintide
+ Semaglutide
StrongCagrilintide (amylin receptor agonist) and semaglutide (GLP-1 receptor agonist) act on distinct receptor systems to produce synergistic weight loss through complementary mechanisms — central satiety via amylin pathways plus incretin-mediated glucose control and appetite suppression via GLP-1. Co-formulated as CagriSema, this combination demonstrates 7.5% greater weight loss versus semaglutide monotherapy in Phase 3 trials with additional benefits on glycemic control and lipid parameters.
- CagriSema
- Cagrilintide 2.4 mg + Semaglutide 2.4 mg
- Frequency
- Once weekly subcutaneous
- Duration
- 26–52 weeks (trial data)
- Primary benefit
- Enhanced weight loss, improved glycemic control, multi-pathway metabolic modulation
IGF-1 LR3
+ GHRP-6
Multi-pathwayGHRP-6 stimulates endogenous GH release, which drives hepatic IGF-1 synthesis. IGF-1 LR3 provides exogenous, IGFBP-resistant IGF signaling. Combining upstream GH stimulation with downstream IGF receptor activation creates a dual-pathway anabolic effect. However, this bypasses natural feedback and carries compounded mitogenic risk.
- GHRP-6
- 100–200 mcg SQ · 2–3× daily
- IGF-1 LR3
- Research doses variable · post-workout typical in animal models
- Note
- Research context only — no human protocols exist
- Primary benefit
- Theoretical maximal anabolic signaling (GH + IGF axes)
+ Ipamorelin
Multi-pathwayIpamorelin (selective GHRP) stimulates pulsatile GH release without cortisol/prolactin elevation. IGF-1 LR3 directly activates IGF-1R independent of GH. This stack targets both upstream (GH secretion) and downstream (IGF receptor) nodes but eliminates physiological feedback, raising safety concerns around unchecked proliferation.
- Ipamorelin
- 200–300 mcg SQ · evening
- IGF-1 LR3
- Research doses only · timing variable
- Caution
- No human data; animal/in vitro only
- Primary benefit
- Dual-axis anabolic signaling (theoretical)